### Delamanid

**Indication:** Multi-drug resistant Mycobacterium tuberculosis  
**ICD11 code:** ML32.00

**INN:** Delamanid  
**Medicine type:** Chemical agent

**List type:** Complementary

**Additional notes:** Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control.

**Formulations:** Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible) (EMLc)

**EML status history:**
- First added in 2015 (TRS 994)
- Changed in 2017 (TRS 1006)
- Changed in 2019 (TRS 1021)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex:** All

**Age:** Also recommended for children

**Therapeutic alternatives:** The recommendation is for this specific medicine

**Patent information:** Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org). Read more about patents.

**Wikipedia:** Delamanid

**DrugBank:** Delamanid

---

**Summary of evidence and Expert Committee recommendations**

The Expert Committee recommended the removal of the age restrictions from the listing of delamanid on the EML and EMLc, consistent with the recommendations for use of delamanid in current WHO guidelines for management of tuberculosis in children and adolescents.